Integrity Wealth Advisors Inc. Takes $977,000 Position in Amgen Inc. (NASDAQ:AMGN)

Integrity Wealth Advisors Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,750 shares of the medical research company's stock, valued at approximately $977,000. Amgen comprises 0.7% of Integrity Wealth Advisors Inc.'s investment portfolio, making the stock its 21st largest holding.

Other institutional investors also recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Amgen during the 3rd quarter worth approximately $1,588,000. Morse Asset Management Inc acquired a new position in Amgen during the 3rd quarter worth approximately $806,000. Tudor Financial Inc. purchased a new stake in shares of Amgen during the 3rd quarter worth $3,281,000. World Investment Advisors LLC grew its stake in shares of Amgen by 48.4% during the third quarter. World Investment Advisors LLC now owns 11,083 shares of the medical research company's stock worth $3,571,000 after purchasing an additional 3,616 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in Amgen in the third quarter valued at $408,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent analyst reports. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Morgan Stanley lifted their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 9th. StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, UBS Group raised their price target on Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen has a consensus rating of "Moderate Buy" and a consensus target price of $314.91.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is owned by corporate insiders.

Amgen Trading Down 1.9 %

Shares of AMGN stock traded down $5.35 on Friday, reaching $277.29. 4,371,822 shares of the stock were exchanged, compared to its average volume of 2,793,769. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market cap of $149.09 billion, a P/E ratio of 36.73, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a 50 day moving average of $303.04 and a two-hundred day moving average of $294.04.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.